Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 13,062 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: ABDOMINAL AORTIC ANEURYSMS
Interventions: AneuRx AAA stent graft / Talent AAA stent graft; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 65
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 57 more

Conditions: Mantle Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 374
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 105
States / cities: Fremont, California • Los Angeles, California • San Francisco, California + 37 more

Conditions: Biliary Cirrhosis, Primary
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 39
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: Diabetic Kidney Disease
Interventions: MEDI3506, Placebo, Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more

Conditions: Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2031
U.S. locations: 22
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Gainesville, Florida + 17 more

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 24
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 16 more

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions: Dexamethasone, Resection, Stereotactic Radiosurgery; Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus
Interventions: FK614; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 36
States / cities: Ozark, Alabama • Tucson, Arizona • Cypress, California + 29 more

Conditions: Postoperative Pain, Acute
Interventions: PF614 capsule, Placebo; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Houston, Texas • Salt Lake City, Utah

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Multiple Sclerosis
Interventions: Fingolimod, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 100
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more

Conditions: Urothelial Cancer, Bladder Cancer
Interventions: Dato-DXd, Carboplatin, Cisplatin, Gemcitabine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 38
States / cities: Fullerton, California • Glendale, California • La Jolla, California + 34 more

Conditions: Major Depressive Disorder
Interventions: ABX-002, Placebo; Drug · Other
Lead sponsor: Autobahn Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 44 more

Conditions: Type 2 Diabetes, Cortisol Excess
Interventions: clofutriben, Placebo; Drug
Lead sponsor: Sparrow Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 61
States / cities: Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 53 more

Conditions: Major Depressive Disorder
Interventions: AGN-241751, Placebo; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • Garden Grove, California • Atlanta, Georgia + 2 more

Conditions: Bipolar I Disorder
Interventions: Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: tirasemtiv; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 41
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 36 more

Conditions: Endometrial Neoplasms
Interventions: pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more

Conditions: Chronic Myeloid Leukemia
Interventions: AMN107; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 59
States / cities: Mobile, Alabama • Tucson, Arizona • Duarte, California + 48 more

Conditions: Graft Versus Host Disease, Acute
Interventions: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Placebo, Corticosteroids; Biological · Drug
Lead sponsor: Cynata Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 9 more

Conditions: Dermatitis, Atopic Dermatitis
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 15
States / cities: Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 10 more

Conditions: Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract, Penile Cancer, Non-adenocarcinoma Prostate Cancer, Refractory Germ-cell, High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma
Interventions: Ipilimumab, Nivolumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 6
States / cities: La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Schizophrenia
Interventions: ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Atlanta, Georgia • Hoffman Estates, Illinois • St Louis, Missouri + 3 more

Search by objective public record fields.

The (PIVOTAL) Study

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

A Phase 2b Diabetic Kidney Disease Study

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients

Radiosurgery Before Surgery for the Treatment of Brain Metastases

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Zelquistinel in the Treatment of Adults With Major Depressive Disorder

Staccato Loxapine in Agitated Patients With Bipolar Disorder

A Study for Patients Who Completed VITALITY-ALS (CY 4031)

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia